L. Pettersson

Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity.

D. Gisselsson, P. D. Dal Cin, M. Höglund, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Measurable residual disease testing for personalized treatment of acute myeloid leukemia

L. Pettersson, M. Ehinger, Louise Pettersson, 2019, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1‐mutated acute myeloid leukemia

L. Saal, V. Lazarevic, L. Pettersson, 2021, International journal of laboratory hematology.

Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis

L. Saal, G. Juliusson, V. Lazarevic, 2020, Leukemia & lymphoma.

Patient‐tailored analysis of minimal residual disease in acute myeloid leukemia using next‐generation sequencing

E. Kristiansson, H. Garelius, T. Samuelsson, 2017, European journal of haematology.

Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.

T. Fioretos, G. Juliusson, V. Lazarevic, 2018, Blood.

Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years

G. Juliusson, V. Lazarevic, L. Pettersson, 2021, Leukemia & lymphoma.

Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia

G. Juliusson, L. Pettersson, M. Ehinger, 2016, Genes, chromosomes & cancer.